PKI PerkinElmer Inc.

PerkinElmer to Present at BofA Global Healthcare Conference 2020

WALTHAM, Mass.--(BUSINESS WIRE)--

(NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the BofA Global Healthcare Conference 2020 on Wednesday, September 16, 2020 at 10:05 a.m. ET.

Prahlad Singh, president and chief executive officer of PerkinElmer, will provide an overview of the Company and its strategic priorities.

A live audio webcast of the presentation will also be available on the section of the Company’s website at . A replay of the presentation will be posted on the PerkinElmer website after the event and will be available for 90 days following.

About PerkinElmer

PerkinElmer, Inc. is a global leader focused on innovating for a healthier world. The Company reported revenue of approximately $2.9 billion in 2019, has about 13,000 employees serving customers in 190 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE, or at .

EN
04/09/2020

Underlying

PKIPerkinElmer Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PerkinElmer Inc.

PKI PerkinElmer In...

Revvity, Inc. - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

PKI PERKINELMER INC.
12/08/25 December 8, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.69
ILMN ILLUMINA INC.
WAT Waters Corporat... ... (+28)

Vermilion Compass: Weekly Equity Strategy

Back to Near-Term Bullish on SPX and QQQ We downgraded our near-term outlook on the S&P 500 (SPX) and Nasdaq 100 (QQQ) to neutral last week (11/19/25 Compass), after being bullish since our 4/22/25 Compass, while maintaining our intermediate-term bullish outlook (as of our 5/14/25 Compass). Crucial support levels of 6480-6520 on SPX and $580-$583 on QQQ held last week, and we are right back to being near-term bullish as long as these support levels continue to hold. Just know that SPX could see...

ILMN ILLUMINA INC.
WAT WATERS CORPORATION
VCYT VERACYTE INC
TMO THERMO FISHER SCIENTIFIC INC.
RGEN REPLIGEN CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
IDXX IDEXX LABORATORIES INC.
HALO HALOZYME THERAPEUTICS INC.
EXEL EXELIXIS INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ANGO ANGIODYNAMICS INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
IONS IONIS PHARMACEUTICALS INC.
PKI PERKINELMER INC.
UTHR UNITED THERAPEUTICS CORPORATION
FLGT FULGENT GENETICS
MDGL MADRIGAL PHARMACEUTICALS
CELC CELCUITY
DNLI DENALI THERAPEUTICS INC
STE STERIS PLC
CSTL CASTLE BIOSCIENCES
TXG 10X GENOMICS INC CLASS A
VIR VIR BIOTECHNOLOGY
RPRX ROYALTY PHARMA PLC CLASS A
ADPT ADAPTIVE BIOTECHNOLOGIES
PRPO PRECIPIO INC.
11/25/25 November 25, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 42.69
DHR DANAHER CORPORA...
ILMN ILLUMINA INC. ... (+17)

Vermilion Compass: Weekly Equity Strategy

6550-6569 S&P 500 Support Holding For Now After 5.5-months, the S&P 500 (SPX) has now failed to break and stay below the its 20-day MA. However, 6569 has been our level that needs to break in order for us to have confidence that a pullback has begun; SPX made a low of 6551 on Friday (less than 20 points or 0.3% from our 6569 level), meaning it was not a decisive breakdown (in time or price). As a result, our near-term bullish outlook since our 4/22/25 Compass remains intact, and it will stay t...

DHR DANAHER CORPORATION
ILMN ILLUMINA INC.
WAT WATERS CORPORATION
TECH BIO-TECHNE CORPORATION
PACB PACIFIC BIOSCIENCES OF CALIFORNIA INC.
CRL CHARLES RIVER LABORATORIES INTERNATIONAL INC.
BRKR BRUKER CORPORATION
A AGILENT TECHNOLOGIES INC.
BIO BIO-RAD LABORATORIES INC. CLASS A
PKI PERKINELMER INC.
NTLA INTELLIA THERAPEUTICS INC.
CRSP CRISPR THERAPEUTICS AG
AVTR AVANTOR INC.
PSNL PERSONALIS
TWST TWIST BIOSCIENCE
PGEN PRECIGEN INC
OGEN ORAGENICS INC.
10/23/25 October 23, 2025 1 EN
PKI PerkinElmer In...

Moody's Ratings announces completion of a periodic review of ratings o...

Moody's Ratings (Moody's) has completed a periodic review of the ratings of Revvity, Inc. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 24 June 2025 in which we reassessed the appropriateness of the ratings in the context of the ...

PKI PERKINELMER INC.
06/25/25 June 25, 2025 1 EN
 PRESS RELEASE
Free
PKI PerkinElmer In...

Revvity’s EUROIMMUN Spearheads Cutting-Edge Diagnostic Analysis with N...

WALTHAM, Mass.--(BUSINESS WIRE)-- (NYSE: RVTY), announced today that its business has launched the (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. “Traditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,”...

June 1, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch